http://www.bing.com/news/search?q=boehringer&FORM=BNFD&format=rssSearch resultshttp://www.bing.com/rsslogo.gifhttp://www.bing.com/news/search?q=boehringer&FORM=BNFD&format=rssCopyright \xc2\xa9 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2ffinance.yahoo.com%2fnews%2fboehringer-expand-oncology-presence-572m-113949111.html&c=13857950405366428033&mkt=en-usBoehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer therapies for tumours that rely on the alternative lengthening of telomeres ...Tue, 22 Apr 2025 17:00:00 GMTYahoo Financehttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fmarkets.businessinsider.com%2fnews%2fstocks%2fjascayd-nerandomilast-approved-in-japan-advancing-global-access-to-a-new-ipf-and-ppf-treatment-1036170392&c=3380647038894210282&mkt=en-usNot intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary ...Sun, 17 May 2026 23:22:00 GMTMarkets Insiderhttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fmarkets.businessinsider.com%2fnews%2fstocks%2fboehringer-ingelheim-licenses-preclinical-antibody-program-from-immunitas-therapeutics-to-advance-treatments-for-chronic-inflammatory-diseases-1036142760&c=4357375488040516181&mkt=en-usThe first‑in‑class antibody program is designed to selectively target pathogenic cells, with the potential to deliver deeper and more durable ...Tue, 12 May 2026 05:24:00 GMTMarkets Insiderhttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fwww.fiercebiotech.com%2fbiotech%2fboehringer-furthers-inflammatory-expansion-eu407m-biobuck-bet-immunitas-asset&c=4310500935995894085&mkt=en-usBoehringer Ingelheim has put up 407.5 million euros ($478 million) in biobucks to secure global rights to a first‑in‑class antibody Immunitas Therapeutics is developing for chronic inflammatory and ...Tue, 12 May 2026 06:56:00 GMTFierce Biotechhttp://www.bing.com/th?id=ONUT.yTknwKmP2jXpT5cau4DxoQ&pid=Newsw={0}&h={1}&c=1420001500http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fwww.msn.com%2fen-us%2fhealth%2fother%2fboehringer-ingelheim-s-obesity-drug-helps-lose-fat-rather-than-muscle-late-stage-trial-shows%2far-AA21Tb8r&c=7855955779408717728&mkt=en-usEXCLUSIVE: Survodutide shows potential to predominantly target visceral fat, its Chief Executive Shashank Deshpande said in an interview.Mon, 27 Apr 2026 23:48:00 GMTThe Wall Street Journal on MSNhttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fwww.fiercepharma.com%2fmanufacturing%2fboehringer-ingelheim-commits-eu120m-expand-greek-plant-add-capacity-jardiance&c=10897528899228345917&mkt=en-usEven as obesity and diabetes heavyweights Eli Lilly and Novo Nordisk command headlines with their global manufacturing expansions, Boehringer Ingelheim is getting in on the action. Thursday, ...Fri, 12 Jan 2024 01:14:00 GMTFiercePharmahttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fwww.pharmabiz.com%2fNewsDetails.aspx%3faid%3d185995%26sid%3d2&c=6974832264701667168&mkt=en-usBoehringer Ingelheim’s Jascayd approved in Japan to treat idiopathic pulmonary fibrosis & progressive pulmonary fibrosis: Ingelheim, Germany Tuesday, May 19, 2026, 13:00 Hrs [IS ...Tue, 19 May 2026 00:30:00 GMTPharmabizhttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fwww.nasdaq.com%2fpress-release%2fboehringer-ingelheim-and-zealand-pharma-receive-fda-fast-track-designation-for&c=17505686158357380298&mkt=en-usFDA’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfill the unmet medical needs of people affected by NASH Boehringer ...Wed, 02 Jun 2021 01:04:00 GMTNasdaqhttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fpharmaphorum.com%2fnews%2fboehringer-brainomix-plan-new-trial-lung-fibrosis-ai&c=13729341398024159553&mkt=en-usBoehringer Ingelheim's alliance with digital health company Brainomix on an AI-enabled tool for diagnosing interstitial lung diseases (ILDs) has been broadened with a large-scale, prospective clinical ...Wed, 13 May 2026 06:32:00 GMTpharmaphorumhttp://www.bing.com/th?id=ONUT.Y9EYtXW4L1b-szS5gfz2yg&pid=Newsw={0}&h={1}&c=14960540http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fwww.msn.com%2fen-us%2fnews%2ftechnology%2fboehringer-ingelheim-launches-ai-centre-in-london%2far-AA21l0ES&c=13846080451325785264&mkt=en-usThe new site will focus on the use of AI models for purposes including the discovery and development of targeted medicines for patients with unmet medical needs.Mon, 20 Apr 2026 08:36:09 GMTPharmaceutical Technology on MSNhttp://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=6a0e39f99ebd4f9a84bc60323235bd53&url=https%3a%2f%2fwww.scotusblog.com%2fcases%2fboehringer-ingelheim-pharmaceuticals-inc-v-department-of-health-and-human-services%2f&c=11206901449956839813&mkt=en-usApr 8, 2026 Brief of respondents Department of Health and Human Services, et al. in opposition filed. Recommended Citation: Boehringer Ingelheim Pharmaceuticals, Inc. v. Department of Health and Human ...Tue, 14 Apr 2026 12:34:00 GMTSCOTUSblog